Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer


Study Number
73318
Phase
I
Purpose

This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Full Title

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion-Positve Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation

ClinicalTrials.Gov ID
NCT03157128

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.